Hcw Biologics Inc. HCWB
We take great care to ensure that the data presented and summarized in this overview for HCW Biologics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HCWB
View all-
Avantax Planning Partners, Inc.280KShares$81,0660.01% of portfolio
-
Geode Capital Management, LLC Boston, MA183KShares$53,1450.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL181KShares$52,4340.0% of portfolio
-
Cresset Asset Management, LLC Chicago, IL132KShares$38,2770.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX84.7KShares$24,5630.0% of portfolio
-
Pullen Investment Management, LLC Bradenton, FL75.1KShares$21,7830.03% of portfolio
-
Hrt Financial LP New York, NY46.5KShares$13,4840.0% of portfolio
-
Black Rock Inc. New York, NY42.7KShares$12,3710.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA37.7KShares$10,9260.0% of portfolio
-
Ae Wealth Management LLC30KShares$8,7000.0% of portfolio
Latest Institutional Activity in HCWB
Top Purchases
Top Sells
About HCWB
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Insider Transactions at HCWB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 20
2024
|
Hing C Wong Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
739,288
+4.4%
|
$739,288
$1.4 P/Share
|
|
Feb 20
2024
|
Rebecca Byam Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
760,714
+35.5%
|
$760,714
$1.4 P/Share
|
|
Feb 20
2024
|
Lee Flowers SVP of Business Development |
BUY
Grant, award, or other acquisition
|
Direct |
71,429
+27.3%
|
$71,429
$1.4 P/Share
|
|
Feb 20
2024
|
Scott T Garrett |
BUY
Grant, award, or other acquisition
|
Indirect |
142,858
+34.78%
|
$142,858
$1.4 P/Share
|
|
Feb 20
2024
|
Lisa M. Giles |
BUY
Grant, award, or other acquisition
|
Direct |
35,715
+49.93%
|
$35,715
$1.4 P/Share
|
|
Feb 20
2024
|
Rick S. Greene |
BUY
Grant, award, or other acquisition
|
Direct |
35,714
+44.73%
|
$35,714
$1.4 P/Share
|
|
Dec 11
2023
|
Peter Rhode Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+15.3%
|
$0
$0.14 P/Share
|
|
Dec 08
2023
|
Lee Flowers SVP of Business Development |
BUY
Exercise of conversion of derivative security
|
Direct |
7,501
+5.94%
|
$0
$0.14 P/Share
|
|
Nov 17
2023
|
Peter Rhode Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+19.11%
|
$0
$0.14 P/Share
|
|
Oct 19
2023
|
Rebecca Byam Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,249
+7.07%
|
$0
$0.14 P/Share
|
|
Sep 14
2023
|
Hing C Wong Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,800
+0.01%
|
$3,600
$2.08 P/Share
|
|
Sep 14
2023
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
1,041
+2.96%
|
$2,082
$2.07 P/Share
|
|
Sep 13
2023
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.86%
|
$10,000
$2.1 P/Share
|
|
Sep 13
2023
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
546
+1.67%
|
$1,092
$2.03 P/Share
|
|
Sep 12
2023
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.87%
|
$10,000
$2.09 P/Share
|
|
Sep 12
2023
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
500
+3.14%
|
$1,000
$2.05 P/Share
|
|
Sep 11
2023
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.88%
|
$10,000
$2.05 P/Share
|
|
Sep 11
2023
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
99
+0.66%
|
$198
$2.05 P/Share
|
|
Sep 08
2023
|
Gary M Winer |
BUY
Open market or private purchase
|
Direct |
1
+0.01%
|
$1
$1.9 P/Share
|
|
Sep 08
2023
|
Rebecca Byam Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.89%
|
$10,000
$2.02 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.79M shares |
|---|---|
| Exercise of conversion of derivative security | 36.5K shares |